RxDoctor Payments DataLook up a doctor →

Ivonne Fraga Berrios, MD

Neurology · Hato Rey, PRNPI 1033116264

Payments from drug & device makers

$1,692,241in general payments, 2019–2025

Across 119 payments — averaging $14,221 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$1.5M
  • AbbVie$71K
  • Eli Lilly$31K
  • Avanir Pharmaceuticals, Inc.$25K
  • E.r. Squibb & Sons, L.L.C.$22K
  • Genentech, Inc.$18K
  • plus $16K from 11 others
$147,860in research payments, 2019–2025

Across 11 payments — averaging $13,442 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$132K
  • Eli Lilly$16K

What the payments were for

  • Consulting fees$12,39055%
  • Speaking & faculty fees$6,82530%
  • Travel & lodging$2,16410%
  • Food & beverage$1,1505%
  • Education$180%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,692,241 in reported general payments places this provider in the 95th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,878
Medicare patients
59
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide101$48,762
Memantine Hcl ErMemantine Hcl469$39,474
Rivastigmine263$37,319
Keppra XrLevetiracetam24$16,277
Galantamine ErGalantamine Hbr161$14,881
UbrelvyUbrogepant14$14,282
Donepezil Hcl520$10,783
Emgality PenGalcanezumab-Gnlm14$9,877
Pregabalin206$4,883
Duloxetine Hcl226$4,383
Gabapentin311$3,472
Carbidopa-LevodopaCarbidopa/Levodopa115$2,894
Pyridostigmine Bromide34$2,550
Pyridostigmine Bromide ErPyridostigmine Bromide12$2,392
RivastigmineRivastigmine Tartrate50$2,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$92$48,762101 claims
AbbVieUbrelvy$70,684$14,28214 claims
Lilly USA, LLCOlanzapine$7,898$84761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 neurology providers in Puerto Rico.

Other neurology in Hato Rey

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →